Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics’ anti-CD22 monoclonal antibody

[at noodls] – Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics’ anti-CD22 monoclonal antibody CD22 is a well-validated target for hematological … more

View todays social media effects on IMMU

View the latest stocks trending across Twitter. Click to view dashboard

See who Immunomedics is hiring next, click here to view